A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma

It is difficult for traditional therapies to further improve the prognosis of hepatocellular carcinoma (LIHC), and immunotherapy is considered to be a promising approach to overcome this dilemma. However, only a minority of patients benefit from immunotherapy, which greatly limits its application. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianlin Zhu, Junxi Kuang, Yi Yang, Lei Zhang, Bo Leng, Risheng She, Ling Zou
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2023/6645476
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849411693670563840
author Jianlin Zhu
Junxi Kuang
Yi Yang
Lei Zhang
Bo Leng
Risheng She
Ling Zou
author_facet Jianlin Zhu
Junxi Kuang
Yi Yang
Lei Zhang
Bo Leng
Risheng She
Ling Zou
author_sort Jianlin Zhu
collection DOAJ
description It is difficult for traditional therapies to further improve the prognosis of hepatocellular carcinoma (LIHC), and immunotherapy is considered to be a promising approach to overcome this dilemma. However, only a minority of patients benefit from immunotherapy, which greatly limits its application. Therefore, it is particularly urgent to elucidate the specific regulatory mechanism of tumor immunity so as to provide a new direction for immunotherapy. NOP2/Sun RNA methyltransferase 3 (NSUN3) is a protein with RNA binding and methyltransferase activity, which has been shown to be involved in the occurrence and development of a variety of tumors. At present, the relationship between NSUN3 and immune implication in LIHC has not been reported. In this study, we first revealed that NSUN3 expression is upregulated in LIHC and that patients with high NSUN3 expression have a poor prognosis through multiple databases. Pathway enrichment analysis demonstrated that NSUN3 may be participated in cell adhesion and cell matrix remodeling. Next, we obtained a set of genes coexpressed with NSUN3 (NCGs). Further LASSO regression was performed based on NCGs, and a risk score model was constructed, which proved to have good predictive power. In addition, Cox regression analysis revealed that the risk score of NCGs model was an independent risk factor for LIHC patients. Moreover, we established a nomogram based on the NCGs-related model, which was verified to have a good predictive ability for the prognosis of LIHC. Furthermore, we investigated the relationship between NCGs-related model and immune implication. The results implied that our model was closely related to immune score, immune cell infiltration, immunotherapy response, and multiple immune checkpoints. Finally, the pathway enrichment analysis of NCGs-related model showed that the model may be involved in the regulation of various immune pathways. In conclusion, our study revealed a novel role of NSUN3 in LIHC. The NSUN3-based prognostic model may be a promising biomarker for inspecting the prognosis and immunotherapy response of LIHC.
format Article
id doaj-art-628674d421404dccbc1aef259b4be364
institution Kabale University
issn 1466-1861
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-628674d421404dccbc1aef259b4be3642025-08-20T03:34:41ZengWileyMediators of Inflammation1466-18612023-01-01202310.1155/2023/6645476A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular CarcinomaJianlin Zhu0Junxi Kuang1Yi Yang2Lei Zhang3Bo Leng4Risheng She5Ling Zou6Dongguan Institute of Clinical Cancer ResearchDepartment of Cardiovascular MedicineDongguan Institute of Clinical Cancer ResearchDongguan Institute of Clinical Cancer ResearchDongguan Institute of Clinical Cancer ResearchDongguan Institute of Clinical Cancer ResearchDongguan Institute of Clinical Cancer ResearchIt is difficult for traditional therapies to further improve the prognosis of hepatocellular carcinoma (LIHC), and immunotherapy is considered to be a promising approach to overcome this dilemma. However, only a minority of patients benefit from immunotherapy, which greatly limits its application. Therefore, it is particularly urgent to elucidate the specific regulatory mechanism of tumor immunity so as to provide a new direction for immunotherapy. NOP2/Sun RNA methyltransferase 3 (NSUN3) is a protein with RNA binding and methyltransferase activity, which has been shown to be involved in the occurrence and development of a variety of tumors. At present, the relationship between NSUN3 and immune implication in LIHC has not been reported. In this study, we first revealed that NSUN3 expression is upregulated in LIHC and that patients with high NSUN3 expression have a poor prognosis through multiple databases. Pathway enrichment analysis demonstrated that NSUN3 may be participated in cell adhesion and cell matrix remodeling. Next, we obtained a set of genes coexpressed with NSUN3 (NCGs). Further LASSO regression was performed based on NCGs, and a risk score model was constructed, which proved to have good predictive power. In addition, Cox regression analysis revealed that the risk score of NCGs model was an independent risk factor for LIHC patients. Moreover, we established a nomogram based on the NCGs-related model, which was verified to have a good predictive ability for the prognosis of LIHC. Furthermore, we investigated the relationship between NCGs-related model and immune implication. The results implied that our model was closely related to immune score, immune cell infiltration, immunotherapy response, and multiple immune checkpoints. Finally, the pathway enrichment analysis of NCGs-related model showed that the model may be involved in the regulation of various immune pathways. In conclusion, our study revealed a novel role of NSUN3 in LIHC. The NSUN3-based prognostic model may be a promising biomarker for inspecting the prognosis and immunotherapy response of LIHC.http://dx.doi.org/10.1155/2023/6645476
spellingShingle Jianlin Zhu
Junxi Kuang
Yi Yang
Lei Zhang
Bo Leng
Risheng She
Ling Zou
A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
Mediators of Inflammation
title A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
title_full A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
title_fullStr A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
title_full_unstemmed A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
title_short A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma
title_sort prognostic model based on nsun3 was established to evaluate the prognosis and response to immunotherapy in liver hepatocellular carcinoma
url http://dx.doi.org/10.1155/2023/6645476
work_keys_str_mv AT jianlinzhu aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT junxikuang aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT yiyang aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT leizhang aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT boleng aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT rishengshe aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT lingzou aprognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT jianlinzhu prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT junxikuang prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT yiyang prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT leizhang prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT boleng prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT rishengshe prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma
AT lingzou prognosticmodelbasedonnsun3wasestablishedtoevaluatetheprognosisandresponsetoimmunotherapyinliverhepatocellularcarcinoma